Alpha-synuclein (UniProt P37840; also known as NACP, Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor, Synuclein alpha-140) is encoded by the SNCA (also known as NACP, PARK1, PARK4) gene (Gene ID 6622) in human. Pathological aggregates are common features of many neurodegenerative diseases, such as tau neurofibrillary tangles (NFTs) in Alzheimer's disease (AD) and frontotemporal degeneration, and alpha-synuclein (alpha-syn or alphaS) Lewy bodies (LBs) in Parkinson's disease (PD) and dementia with LBs (DLB). Alpha-synuclein is a phospholipid-binding protein concentrated in presynaptic terminals where it promotes SNARE complex formation and modulates synaptic functions. Alpha-synuclein is the major component of pathologic inclusions that characterize PD, DLB, and multiple system atrophy (MSA). Research shows that alphaS exists not only as unfolded monomers, but in large part also as multimers, principally as ~60 kDa tetramers composed of four N-acetylated alphaS, that assume alpha-helical conformation and resist aggregation. PD-causing alphaS missense mutations are found to shift cellular alphaS from tetramers/multimers to monomers, indicating that decreased alpha-helical tetramers and increased unfolded monomers initiate pathogenesis. In addition, both casein kinase-1 (CK-1) and CK-2 can catalyze the phosphorylation of alphaS on Ser129, and Ser129-phosphorylated alphaS is found in alphaS inclusions.
Synonyms: Alpha-synuclein, NACP, Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor, Synuclein alpha-140
Application: Immunohistochemistry Analysis: A 1:250 dilution from a representative lot detected alpha-synuclein in human cerebellum, cerebral cortex, and pancreas tissue sections.ELISA Analysis: A 1:74.6 dilution from a representative lot (preconjugated with Sulfo tag) detected recombinant human alpha-synuclein (0.2-40 ng/mL) captured by clone 2F12 (Cat. No. MABN1817; 200 ng/30 µL/well for coating) in a sandwich ELISA application (Courtesy of Tim Bartels, Ph.D., Brigham and Women's Hospital, Boston, MA, U.S.A.).Immunoprecipitation Analysis: 4 µL from a representative lot immunoprecipitated alpha-synuclein from 50 µg of HEL human erythroleukemia cell lysate (Courtesy of Tim Bartels, Ph.D., Brigham and Women's Hospital, Boston, MA, U.S.A.).ELISA Analysis: A representative lot (preconjugated with Sulfo tag) detected both endogenous alpha-synuclein (alphaS) from human cortical homogenate, as well the exogenously expressed wild type and familial PD (fPD) alphaS mutants (A30P, E46K, H50Q, G51D, A53T) from sytosolic extracts of transfected M17D human neuroblastoma cells in a sandwich ELISA application utilizing clone 2F12 (Cat. No. MABN1817) as the capture antibody (Dettmer, U., et al. (2015). Nat. Commun. 6:7314).ELISA Analysis: A representative lot (preconjugated with Sulfo tag) detected both pre-aggregated fibrillar recombinant -synuclein as well as partially purified Lewy bodies (LBs) from a DLB (dementia with LBs) patient with or without prior sample denaturing by boiling with 2% SDS in a sandwich ELISA application utilizing clone 2F12 (Cat. No. MABN1817) as the capture antibody (Dettmer, U., et al. (2015). Nat. Commun. 6:7314).
Other Notes: Concentration: Please refer to lot specific datasheet.